top of page
Antibody System Anti-HLA-A2-peptide (FMNKFIYEI) Complex Monoclonal Antibody (AMC

Antibody System Anti-HLA-A2-peptide (FMNKFIYEI) Complex Monoclonal Antibody (AMC

Overview
This specialized monoclonal antibody specifically targets the specific major histocompatibility complex (MHC) class I complex formed by the Human Leukocyte Antigen A2 (HLA-A2) molecule presenting the tumor-associated antigenic peptide fragment FMNKFIYEI. In cellular immunity, HLA-A2 presents endogenous peptide epitopes on the cell surface for surveillance by cytotoxic T lymphocytes (CTLs). The specific peptide sequence presented in this complex is a highly relevant epitope derived from Alpha-fetoprotein (AFP), an oncofetal glycoprotein typically suppressed after birth but frequently re-expressed and secreted at high levels in hepatocellular carcinoma (HCC) and certain germ cell tumors. Monoclonal antibodies that target specific peptide-MHC complexes with T-cell receptor-like (TCR-like) specificity serve as valuable instruments for directly validating specific antigen presentation trends, tracking tumor cell immune escape mechanisms, and evaluating targeted immunotherapies like CAR-T or bispecific T-cell engagers (BiTEs). Generated from mammalian expression systems using mouse hybridoma clone AMC-17, this purified IgG1 monoclonal antibody provides high-affinity, structural conformation-specific target recognition without binding to empty HLA-A2 molecules or alternative HLA-peptide configurations.
 
DATASHEET

  • PRODUCT INFO

    Key Features and Specifications

    • TCR-like Monoclonal Precision: Engineered from mouse clone AMC-17 to recognize a highly precise spatial conformation formed uniquely by the binding of the FMNKFIYEI peptide within the HLA-A2 groove.

    • Targeted Oncofetal Biomarker: Functions as an elite analytical tool for monitoring AFP-derived peptide presentation metrics on the surface of HLA-A2-positive neoplastic cells.

    • High Purity Profile: Verified at greater than 95 percent purity via SDS-PAGE evaluation, achieved through advanced Protein A/G affinity chromatography from cell culture supernatant.

    • Advanced Biophysical Validation: Optimized for precision screening frameworks, including Surface Plasmon Resonance (SPR) binding kinetics and Enzyme-Linked Immunosorbent Assays (ELISA).

    • High-Stability Liquid Matrix: Supplied at a concentration of 2.18 mg/ml in a ready-to-use 0.01M PBS (pH 7.4) matrix to minimize formulation interference in downstream cell-binding or solid-phase assays.

    Technical Specifications

    • Catalog No.: RHM03036

    • Host Species: Mouse

    • Clone ID: AMC-17 (AMC17)

    • Clonality: Monoclonal

    • Isotype: IgG1

    • Target Complex: HLA-A2 presented FMNKFIYEI peptide complex

    • Accession Numbers: P04439 (HLA-A) and P02771 (AFP)

    • Species Reactivity: Human

    • Concentration: 2.18 mg/ml

    • Expression System: Mammalian Cells

    • Purification: Protein A/G chromatography

    • Form: Liquid solution

    • Storage Buffer: 0.01M PBS, pH 7.4

    Alternative Names: Anti-HLA-A2-AFP peptide complex, HLA-A2-FMNKFIYEI complex specific antibody, TCR-like clone AMC-17.

    Applications and Recommended Dilutions

    This mouse monoclonal IgG1 antibody is highly suited for running quantitative tracking, complex-specific binding kinetics, and localized antigen presentation profiling within immuno-oncology and adoptive cellular therapy tracks. Investigators should utilize the following initial guidelines:

    • Enzyme-Linked Immunosorbent Assay (ELISA): Ideal for validating quantitative target capture arrays, screening soluble peptide-MHC multimer formulations, or solid-phase sandwich screening assemblies.

    • Surface Plasmon Resonance (SPR): Highly optimized for precise biophysical profiling, determination of affinity constants, and assessing off-target displacement kinetics against alternative peptide-MHC complexes.

    • Note: Optimal working dilutions must be determined empirically by the end-user according to specific cell surface antigen densities, transfection parameters, and instrumentation detection thresholds.

    Handling, Reconstitution and Storage

    • Shipping: Distributed under temperature-controlled conditions on blue ice or dry ice to safeguard antibody binding integrity upon arrival.

    • Handling: Ready for immediate use. To minimize structural degradation or contamination risks, it is highly recommended to dispense the liquid solution into single-use working aliquots upon initial receipt.

    • Storage Framework:

      • Short-Term: Store at 4 degrees Celsius for up to 1 to 2 weeks.

      • Medium-Term: Store at minus 20 degrees Celsius for up to 12 months from the date of receipt.

      • Long-Term: Store at minus 80 degrees Celsius in a manual defrost freezer for maximum long-term structural and molecular stability.

      • Note: Avoid repeated freeze-thaw cycles to protect the monoclonal antibody conformation from performance loss.

Heading 6

Related Products

bottom of page